Genentech ( Genentech )


Genentech's picture

Genentech, Inc., is a biotechnology corporation which became a subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche.

Genentech press release, blog etc

03/21/2018 - 12:38 FDA Approves Genentechs Lucentis (Ranibizumab Injection) 0.3 mg Prefilled Syringe for Diabetic Macular Edema and Diabetic Retinopathy
02/13/2018 - 00:40 FDA Grants Priority Review for Genentechs Rituxan (Rituximab) for Pemphigus Vulgaris
02/11/2018 - 01:15 Phase II Data Support Potential for Novel Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody, RG7716, for People With Diabetic Macular Edema
12/20/2017 - 11:18 FDA Approves Genentechs Perjeta (Pertuzumab) for Adjuvant Treatment of Specific Type of Early Breast Cancer
12/10/2017 - 09:49 Phase II Data Showed Genentechs Investigational Polatuzumab Vedotin Plus Bendamustine and Rituxan (BR) Increased Complete Response Rates Compared to BR Alone in Previously Treated Aggressive Lymphoma
12/09/2017 - 23:33 Phase III IMmotion151 Study Showed Genentechs Tecentriq (Atezolizumab) and Avastin (Bevacizumab) Reduced the Risk of Disease Worsening or Death for the Initial Treatment of Certain People with Advanced Kidney Cancer
12/09/2017 - 10:22 Genentechs Hemlibra (emicizumab-kxwh) Continued to Substantially Reduce Bleeds in People with Hemophilia A with Inhibitors
12/06/2017 - 02:04 Genentechs HEMLIBRA (emicizumab-kxwh) Every Four Weeks Controlled Bleeds in Phase III Study in Hemophilia A
12/05/2017 - 17:19 FDA Grants Genentechs Avastin Full Approval for Most Aggressive Form of Brain Cancer
12/04/2017 - 04:37 First Cancer Screen Week Calls on Americans to Act Now Against Cancer by Taking Pledge to Get Screened
11/18/2017 - 22:58 Genentechs Hemlibra (Emicizumab-kxwh) Significantly Reduced Bleeds in Phase III Study in Hemophilia A
11/16/2017 - 13:21 FDA Approves Genentechs Gazyva for Previously Untreated Advanced Follicular Lymphoma
11/16/2017 - 07:28 FDA Approves Genentechs Hemlibra (Emicizumab-kxwh) for Hemophilia A with Inhibitors
11/06/2017 - 12:21 FDA Approves Zelboraf (Vemurafenib) for Erdheim-Chester Disease with BRAF V600 Mutation
11/06/2017 - 10:56 FDA Approves Genentechs Alecensa (Alectinib) as First-Line Treatment for People with Specific Type of Lung Cancer
10/26/2017 - 01:12 New OCREVUS (Ocrelizumab) Data at ECTRIMS Advance Clinical Understanding of Underlying Progression in Multiple Sclerosis
10/24/2017 - 21:07 FDA Accepts Genentechs Supplemental Biologics License Application for Avastin as a Front-Line Treatment for Women with Advanced Ovarian Cancer
10/14/2017 - 21:41 Genentech to Present New Ocrevus (Ocrelizumab) Efficacy & Safety Data in Relapsing and Primary Progressive Forms of Multiple Sclerosis at ECTRIMS